QuantumScape Corporation

QuantumScape Corporation (NYSE: QS) is a leading next-gen solid-state lithium-metal batteries developer for electric vehicles (EVs). Its primary focus is on updating and modernizing energy storage to improve customer satisfaction.

Key Highlights

• The company is yet to report income, and its future performance depends on successful R&D activities.
• Its Q3FY21 (ended September 30, 2021) net income was USD 15.35 million vs. a net loss of 375.85 million reported in Q3FY20, skewed by a USD 68.93 million favourable change in fair value of share warrant liabilities recorded during the current quarter.
• On November 08, 2021, QS announced its manufacturing expansion plans and the development of the QS Campus, which will comprise its current QS-0 site, as well as three new buildings in San Jose, California.
• Stock is currently trading above its crucial short-term (50-day) and long-term (200-day) SMA support levels and its RSI Index is at 68.38.
• The stock is leaning towards the lower end of its 52-week range of USD 13.71 to USD 132.73.
• QS's stock price increased 57.03% in the past month.

Technical Price Chart (as of November 12, 2021). Analysis by Kalkine

Conclusion: Considering the expansion plans, encouraging outlook, and the technical indicators, we recommend a "Watch" rating on the stock at the current price of USD 38.16, down 3.88%, as of November 12, 2021, at 2:03 PM ET.

*The reference data in this report has been partly sourced from REFINITIV.

Arrival

Arrival (NASDAQ: ARVL) focuses on designing and robotic manufacturing of commercial electric vehicles (EV), EV components and associated software. Its primary operations are based in the UK, US, Germany, and Russia.

Key Highlights

• The company is yet to generate sales and expects to record revenues starting H2FY22, subject to successful certification of its EVs.
• Its Q3FY21 (ended September 30, 2021) net loss was EUR 26.39 million, compared to USD 22.33 million reported in Q3FY20.
• The company exited the quarter with a cash balance of EUR 380.70 million and total debt of EUR 149.01 million.
• Stock is currently trading below its crucial short-term (50-day) and long-term (200-day) SMA support levels and its RSI Index is at 42.60.
• The stock is leaning towards the lower end of its 52-week range of USD 9.92 to USD 37.18.
• ARVL's stock price decreased 26.13% and 53.09% in the past six and nine months, respectively.

Technical Price Chart (as of November 12, 2021). Analysis by Kalkine

Conclusion: Considering the technical indicators, lackluster fundamentals, and associated risks, we recommend an "Avoid" rating on the stock at the current price of USD 13.51, down 4.52%, as of November 12, 2021, at 12:58 PM ET.

*The reference data in this report has been partly sourced from REFINITIV.

Cassava Sciences, Inc.

Cassava Sciences, Inc. (NASDAQ: SAVA) is a clinical-stage biotechnology company focused on treating neurodegenerative illnesses, such as Alzheimer's. It currently has two therapies under development, namely simufilam, for the potential treatment of Alzheimer's disease and SavaDx, for the early detection of the possibility of Alzheimer's from a blood sample.

Key Highlights

• The company is yet to generate any revenues from product sales.
• Its Q3FY21 (ended September 30, 2021) net loss expanded to USD 9.56 million from 1.43 million reported in Q3FY20, owing to significantly higher R&D expenses (USD 8.04 million in Q3FY21 vs. USD 0.40 million in Q3FY20).
• The company exited the quarter with a cash balance of USD 241.52 million and no outstanding debt.
• Stock is currently trading above its crucial short-term (50-day) and long-term (200-day) SMA support levels and its RSI Index is at 54.53.
• The stock is leaning towards the lower end of its 52-week range of USD 6.70 to USD 146.16.
• SAVA's stock price increased 24.40% in the past month and fell 44.19% in three months.

Technical Price Chart (as of November 12, 2021). Analysis by Kalkine

Conclusion: Considering the technical indicators, increase in R&D expenses, and other technical indicators, we recommend a "Watch" rating on the stock at the current price of USD 68.41, down 5.55%, as of November 12, 2021, at 2:23 PM ET.

*The reference data in this report has been partly sourced from REFINITIV.

Mustang Bio, Inc.

Mustang Bio, Inc. (NASDAQ: MBIO) is a clinical-stage biopharmaceutical company dedicated to transforming medical advances in cell and gene therapies into viable cures for hematologic malignancies, solid tumors, and rare genetic illnesses.

Key Highlights

• The company is yet to generate any revenues from the sales of its product candidates.
• Its Q3FY21 (ended September 30, 2021) net loss was USD 17.01 million, higher than USD 12.95 million reported in Q3FY20, with R&D expenses for the current period amounting to USD 14.08 million (USD 7.99 million in Q3FY20).
• On November 10, 2021, the company signed a license agreement with Leiden University Medical Centre (LUMC) to treat RAG1 severe combined immunodeficiency using an ex vivo lentiviral gene therapy.
• Stock is currently trading below its crucial short-term (50-day) and long-term (200-day) SMA support levels, and its RSI Index is at 50.89.
• The stock is leaning towards the lower end of its 52-week range of USD 2.10 to USD 5.22.
• MBIO's stock price decreased 11.15% and 13.06% in the past three and six months, respectively.

Technical Price Chart (as of November 12, 2021). Analysis by Kalkine

Conclusion: Considering the technical indicators, recently executed licensing agreement and associated risks, we recommend a "Watch" rating on the stock at the current price of USD 2.43, down 2.19%, as of November 12, 2021, at 1:26 PM ET.

*The reference data in this report has been partly sourced from REFINITIV.

Disclaimer

The advice given by Kalkine Canada Advisory Services Inc. and provided on this website is general information only and it does not take into account your investment objectives, financial situation and the particular needs of any particular person. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. The website www.kalkine.ca is published by Kalkine Canada Advisory Services Inc. The link to our Terms & Conditions has been provided please go through them. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.